Review





Similar Products

95
Miltenyi Biotec cd38
Reconstitution of B-cells over time. To characterize B-cell subsets, peripheral blood mononuclear cells were stained with fluorochrome-conjugated monoclonal antibodies (BD Biosciences) directed against the following antigens: CD45 (V500-C), CD3 (APC), CD19 (APC-H7), CD27 (BV421), IgD (PE), <t>CD38</t> <t>(BV711),</t> CD4 (BV605), and CD8 (PE), as well as 7-AAD (Miltenyi Biotech). The stained cells were then analyzed using multicolor flow cytometry (BD FACS Lyric). The subsets of gated CD19 + cells were identified based on surface marker expression as follows: naïve (CD19+CD27-IgD+), nonswitched memory (CD19+CD27+IgD+), switched memory (CD19+CD27+IgD-), and double negative (CD19+CD27-IgD-); and within the CD19+CD38++ population, we distinguished transitional cells (CD19+CD38++CD27-IgD+), plasmablasts (CD19+CD38++CD27+IgD-), and double-negative CD38 + cells (CD19+CD38++CD27-IgD-). B-cell subsets were expressed as a percentage of the total lymphocyte count. (a) B-cell subpopulations were assessed in 39 patients at baseline and in 36 patients at 3 (M3), 6 (M6), 9 (M9), 12 (M12), and 18 (M18) months following the first rituximab infusion. The 3 patients who did not receive treatment were excluded from the follow-up. Complete depletion of B-cells was observed in all patients at M3 post-rituximab for all B-cell subpopulations. CD19 + cells reappeared 6 months after rituximab infusion. Naive cells re-emerged the most among B-cells, followed by CD38 + cells, transitional cells and finally memory cells. Data are shown as mean values (dots). (b–k) B-cell subpopulations at baseline and at subsequent time points were compared between relapsing patients ( n = 8) and nonrelapsing patients ( n = 19); the 2 patients who received additional anti-CD20 infusions were excluded from subsequent analyses. Data are shown as medians and interquartile range (IQR). P -values were calculated by comparing the median values of each cell subpopulation between relapsing and nonrelapsing patients using a nonparametric, unpaired Mann–Whitney U test.
Cd38, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd38/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
cd38 - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier

86
Johnson & Johnson daratumumab cd38
Reconstitution of B-cells over time. To characterize B-cell subsets, peripheral blood mononuclear cells were stained with fluorochrome-conjugated monoclonal antibodies (BD Biosciences) directed against the following antigens: CD45 (V500-C), CD3 (APC), CD19 (APC-H7), CD27 (BV421), IgD (PE), <t>CD38</t> <t>(BV711),</t> CD4 (BV605), and CD8 (PE), as well as 7-AAD (Miltenyi Biotech). The stained cells were then analyzed using multicolor flow cytometry (BD FACS Lyric). The subsets of gated CD19 + cells were identified based on surface marker expression as follows: naïve (CD19+CD27-IgD+), nonswitched memory (CD19+CD27+IgD+), switched memory (CD19+CD27+IgD-), and double negative (CD19+CD27-IgD-); and within the CD19+CD38++ population, we distinguished transitional cells (CD19+CD38++CD27-IgD+), plasmablasts (CD19+CD38++CD27+IgD-), and double-negative CD38 + cells (CD19+CD38++CD27-IgD-). B-cell subsets were expressed as a percentage of the total lymphocyte count. (a) B-cell subpopulations were assessed in 39 patients at baseline and in 36 patients at 3 (M3), 6 (M6), 9 (M9), 12 (M12), and 18 (M18) months following the first rituximab infusion. The 3 patients who did not receive treatment were excluded from the follow-up. Complete depletion of B-cells was observed in all patients at M3 post-rituximab for all B-cell subpopulations. CD19 + cells reappeared 6 months after rituximab infusion. Naive cells re-emerged the most among B-cells, followed by CD38 + cells, transitional cells and finally memory cells. Data are shown as mean values (dots). (b–k) B-cell subpopulations at baseline and at subsequent time points were compared between relapsing patients ( n = 8) and nonrelapsing patients ( n = 19); the 2 patients who received additional anti-CD20 infusions were excluded from subsequent analyses. Data are shown as medians and interquartile range (IQR). P -values were calculated by comparing the median values of each cell subpopulation between relapsing and nonrelapsing patients using a nonparametric, unpaired Mann–Whitney U test.
Daratumumab Cd38, supplied by Johnson & Johnson, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/daratumumab cd38/product/Johnson & Johnson
Average 86 stars, based on 1 article reviews
daratumumab cd38 - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier

93
R&D Systems cd38
Establishment and characterization of a fibrotic macrophage-muscle fibrosis model. a) Brightfield image of unstimulated RAW264.7 cells in the top chamber of a RAW-C2C12 coculture system, b) Brightfield image of C2C12 cells in the bottom chamber under basal coculture conditions, c) Fluorescence image of C2C12 cells in the bottom chamber exhibiting myotube morphology, d) Fluorescence image confirming the absence of fibrotic marker expression in C2C12 cells under basal conditions, e) Brightfield image of LPS-activated RAW264.7 cells in the top chamber, f) Brightfield image of C2C12 cells in the bottom chamber displaying a myofibroblast-like morphology post-LPS activation, g) Fluorescence image of phenotypic transition of C2C12 cells to myofibroblast-like cells, h) Fluorescence image demonstrating fibrotic protein expression in LPS-treated C2C12 cells (magenta arrow indicates <t>CD38</t> cells). Immunostaining images: In panels c) and g), TGF-β, DAPI, and actin are colored red, blue, and green, respectively. In panels d) and h), COL1, α-SMA, CD38, and DAPI are colored red, blue, magenta, and green, respectively. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Cd38, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd38/product/R&D Systems
Average 93 stars, based on 1 article reviews
cd38 - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

94
Novus Biologicals cd38 antibody 1g7f4
Establishment and characterization of a fibrotic macrophage-muscle fibrosis model. a) Brightfield image of unstimulated RAW264.7 cells in the top chamber of a RAW-C2C12 coculture system, b) Brightfield image of C2C12 cells in the bottom chamber under basal coculture conditions, c) Fluorescence image of C2C12 cells in the bottom chamber exhibiting myotube morphology, d) Fluorescence image confirming the absence of fibrotic marker expression in C2C12 cells under basal conditions, e) Brightfield image of LPS-activated RAW264.7 cells in the top chamber, f) Brightfield image of C2C12 cells in the bottom chamber displaying a myofibroblast-like morphology post-LPS activation, g) Fluorescence image of phenotypic transition of C2C12 cells to myofibroblast-like cells, h) Fluorescence image demonstrating fibrotic protein expression in LPS-treated C2C12 cells (magenta arrow indicates <t>CD38</t> cells). Immunostaining images: In panels c) and g), TGF-β, DAPI, and actin are colored red, blue, and green, respectively. In panels d) and h), COL1, α-SMA, CD38, and DAPI are colored red, blue, magenta, and green, respectively. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Cd38 Antibody 1g7f4, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd38 antibody 1g7f4/product/Novus Biologicals
Average 94 stars, based on 1 article reviews
cd38 antibody 1g7f4 - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

86
Novocastra cd38
Immune pathology, B-cell characterization, and tertiary lymphoid organ-related features. a Diffuse relatively mild sarcolemmal MHC cl. 1 positivity and presence of many MHC cl. 1 positive lymphomonocytic cells in the endomysium, and in a B-cell cluster (arrow). MHC cl. 1 immunohistochemistry; original magnification ×200. b Mild and infrequent sarcolemmal MHC cl. 2 positivity and presence of many MHC cl. 2 positive lymphomonocytic cells in the endomysium, and in a B-cell cluster (arrow). MHC cl. 2 immunohistochemistry; original magnification ×200. c Sarcolemmal complement deposits (arrow) and presence of single necrotic myofibers (arrowhead) that show sarcoplasmic complement deposits. C5b-9 (MAC) immunohistochemistry; original magnification ×200. d Presence of numerous endomysial macrophages and occasional myophagocytoses. CD68 immunohistochemistry; original magnification ×200. e Scattered, individual endomysial T cells. CD8 immunohistochemistry; original magnification ×200. f Focally clustering B cells with a roundish appearance reminiscent of so-called tertiary lymphoid organs (TLOs). CD20 immunohistochemistry; original magnification ×200. g , h TLO-like immune cell clusters show compartmentalization with bcl2-positive B-cell nuclei at the margins and bcl6-positive nuclei in their (germinal) center. Bcl2 (G) and bcl6 (H) immunohistochemistry; original magnification ×600. i Numerous Ki67 + proliferating cells are focally clustering predominantly in germinal centers of TLOs. Ki67 immunohistochemistry; original magnification ×600. j A B-cell cluster contains some CD138-positive plasma cells. CD138 immunohistochemistry; original magnification ×200. k Similarly, those plasma cells and a few B cells are identified by nuclear MUM1 positivity in the light zone of a germinal center. MUM1 immunohistochemistry; original magnification ×200. l <t>CD38-positive</t> plasmablasts are partly proliferating and show co-immunoreactivity with Ki67. CD38 AF488 (green) and Ki67 Cy3 (red) immunofluorescence; original magnification ×200. a – l Scale bar represents 100 µm
Cd38, supplied by Novocastra, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd38/product/Novocastra
Average 86 stars, based on 1 article reviews
cd38 - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier

95
DSMZ 106 bcma cd 38 molp
Immune pathology, B-cell characterization, and tertiary lymphoid organ-related features. a Diffuse relatively mild sarcolemmal MHC cl. 1 positivity and presence of many MHC cl. 1 positive lymphomonocytic cells in the endomysium, and in a B-cell cluster (arrow). MHC cl. 1 immunohistochemistry; original magnification ×200. b Mild and infrequent sarcolemmal MHC cl. 2 positivity and presence of many MHC cl. 2 positive lymphomonocytic cells in the endomysium, and in a B-cell cluster (arrow). MHC cl. 2 immunohistochemistry; original magnification ×200. c Sarcolemmal complement deposits (arrow) and presence of single necrotic myofibers (arrowhead) that show sarcoplasmic complement deposits. C5b-9 (MAC) immunohistochemistry; original magnification ×200. d Presence of numerous endomysial macrophages and occasional myophagocytoses. CD68 immunohistochemistry; original magnification ×200. e Scattered, individual endomysial T cells. CD8 immunohistochemistry; original magnification ×200. f Focally clustering B cells with a roundish appearance reminiscent of so-called tertiary lymphoid organs (TLOs). CD20 immunohistochemistry; original magnification ×200. g , h TLO-like immune cell clusters show compartmentalization with bcl2-positive B-cell nuclei at the margins and bcl6-positive nuclei in their (germinal) center. Bcl2 (G) and bcl6 (H) immunohistochemistry; original magnification ×600. i Numerous Ki67 + proliferating cells are focally clustering predominantly in germinal centers of TLOs. Ki67 immunohistochemistry; original magnification ×600. j A B-cell cluster contains some CD138-positive plasma cells. CD138 immunohistochemistry; original magnification ×200. k Similarly, those plasma cells and a few B cells are identified by nuclear MUM1 positivity in the light zone of a germinal center. MUM1 immunohistochemistry; original magnification ×200. l <t>CD38-positive</t> plasmablasts are partly proliferating and show co-immunoreactivity with Ki67. CD38 AF488 (green) and Ki67 Cy3 (red) immunofluorescence; original magnification ×200. a – l Scale bar represents 100 µm
106 Bcma Cd 38 Molp, supplied by DSMZ, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/106 bcma cd 38 molp/product/DSMZ
Average 95 stars, based on 1 article reviews
106 bcma cd 38 molp - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier

86
Sanofi anti human cd38 antibody anti hcd38
Immune pathology, B-cell characterization, and tertiary lymphoid organ-related features. a Diffuse relatively mild sarcolemmal MHC cl. 1 positivity and presence of many MHC cl. 1 positive lymphomonocytic cells in the endomysium, and in a B-cell cluster (arrow). MHC cl. 1 immunohistochemistry; original magnification ×200. b Mild and infrequent sarcolemmal MHC cl. 2 positivity and presence of many MHC cl. 2 positive lymphomonocytic cells in the endomysium, and in a B-cell cluster (arrow). MHC cl. 2 immunohistochemistry; original magnification ×200. c Sarcolemmal complement deposits (arrow) and presence of single necrotic myofibers (arrowhead) that show sarcoplasmic complement deposits. C5b-9 (MAC) immunohistochemistry; original magnification ×200. d Presence of numerous endomysial macrophages and occasional myophagocytoses. CD68 immunohistochemistry; original magnification ×200. e Scattered, individual endomysial T cells. CD8 immunohistochemistry; original magnification ×200. f Focally clustering B cells with a roundish appearance reminiscent of so-called tertiary lymphoid organs (TLOs). CD20 immunohistochemistry; original magnification ×200. g , h TLO-like immune cell clusters show compartmentalization with bcl2-positive B-cell nuclei at the margins and bcl6-positive nuclei in their (germinal) center. Bcl2 (G) and bcl6 (H) immunohistochemistry; original magnification ×600. i Numerous Ki67 + proliferating cells are focally clustering predominantly in germinal centers of TLOs. Ki67 immunohistochemistry; original magnification ×600. j A B-cell cluster contains some CD138-positive plasma cells. CD138 immunohistochemistry; original magnification ×200. k Similarly, those plasma cells and a few B cells are identified by nuclear MUM1 positivity in the light zone of a germinal center. MUM1 immunohistochemistry; original magnification ×200. l <t>CD38-positive</t> plasmablasts are partly proliferating and show co-immunoreactivity with Ki67. CD38 AF488 (green) and Ki67 Cy3 (red) immunofluorescence; original magnification ×200. a – l Scale bar represents 100 µm
Anti Human Cd38 Antibody Anti Hcd38, supplied by Sanofi, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti human cd38 antibody anti hcd38/product/Sanofi
Average 86 stars, based on 1 article reviews
anti human cd38 antibody anti hcd38 - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier

92
Miltenyi Biotec pe vio770 miltenyi biotec 130 125 522 rat anti mouse cd4
Immune pathology, B-cell characterization, and tertiary lymphoid organ-related features. a Diffuse relatively mild sarcolemmal MHC cl. 1 positivity and presence of many MHC cl. 1 positive lymphomonocytic cells in the endomysium, and in a B-cell cluster (arrow). MHC cl. 1 immunohistochemistry; original magnification ×200. b Mild and infrequent sarcolemmal MHC cl. 2 positivity and presence of many MHC cl. 2 positive lymphomonocytic cells in the endomysium, and in a B-cell cluster (arrow). MHC cl. 2 immunohistochemistry; original magnification ×200. c Sarcolemmal complement deposits (arrow) and presence of single necrotic myofibers (arrowhead) that show sarcoplasmic complement deposits. C5b-9 (MAC) immunohistochemistry; original magnification ×200. d Presence of numerous endomysial macrophages and occasional myophagocytoses. CD68 immunohistochemistry; original magnification ×200. e Scattered, individual endomysial T cells. CD8 immunohistochemistry; original magnification ×200. f Focally clustering B cells with a roundish appearance reminiscent of so-called tertiary lymphoid organs (TLOs). CD20 immunohistochemistry; original magnification ×200. g , h TLO-like immune cell clusters show compartmentalization with bcl2-positive B-cell nuclei at the margins and bcl6-positive nuclei in their (germinal) center. Bcl2 (G) and bcl6 (H) immunohistochemistry; original magnification ×600. i Numerous Ki67 + proliferating cells are focally clustering predominantly in germinal centers of TLOs. Ki67 immunohistochemistry; original magnification ×600. j A B-cell cluster contains some CD138-positive plasma cells. CD138 immunohistochemistry; original magnification ×200. k Similarly, those plasma cells and a few B cells are identified by nuclear MUM1 positivity in the light zone of a germinal center. MUM1 immunohistochemistry; original magnification ×200. l <t>CD38-positive</t> plasmablasts are partly proliferating and show co-immunoreactivity with Ki67. CD38 AF488 (green) and Ki67 Cy3 (red) immunofluorescence; original magnification ×200. a – l Scale bar represents 100 µm
Pe Vio770 Miltenyi Biotec 130 125 522 Rat Anti Mouse Cd4, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pe vio770 miltenyi biotec 130 125 522 rat anti mouse cd4/product/Miltenyi Biotec
Average 92 stars, based on 1 article reviews
pe vio770 miltenyi biotec 130 125 522 rat anti mouse cd4 - by Bioz Stars, 2026-05
92/100 stars
  Buy from Supplier

Image Search Results


Reconstitution of B-cells over time. To characterize B-cell subsets, peripheral blood mononuclear cells were stained with fluorochrome-conjugated monoclonal antibodies (BD Biosciences) directed against the following antigens: CD45 (V500-C), CD3 (APC), CD19 (APC-H7), CD27 (BV421), IgD (PE), CD38 (BV711), CD4 (BV605), and CD8 (PE), as well as 7-AAD (Miltenyi Biotech). The stained cells were then analyzed using multicolor flow cytometry (BD FACS Lyric). The subsets of gated CD19 + cells were identified based on surface marker expression as follows: naïve (CD19+CD27-IgD+), nonswitched memory (CD19+CD27+IgD+), switched memory (CD19+CD27+IgD-), and double negative (CD19+CD27-IgD-); and within the CD19+CD38++ population, we distinguished transitional cells (CD19+CD38++CD27-IgD+), plasmablasts (CD19+CD38++CD27+IgD-), and double-negative CD38 + cells (CD19+CD38++CD27-IgD-). B-cell subsets were expressed as a percentage of the total lymphocyte count. (a) B-cell subpopulations were assessed in 39 patients at baseline and in 36 patients at 3 (M3), 6 (M6), 9 (M9), 12 (M12), and 18 (M18) months following the first rituximab infusion. The 3 patients who did not receive treatment were excluded from the follow-up. Complete depletion of B-cells was observed in all patients at M3 post-rituximab for all B-cell subpopulations. CD19 + cells reappeared 6 months after rituximab infusion. Naive cells re-emerged the most among B-cells, followed by CD38 + cells, transitional cells and finally memory cells. Data are shown as mean values (dots). (b–k) B-cell subpopulations at baseline and at subsequent time points were compared between relapsing patients ( n = 8) and nonrelapsing patients ( n = 19); the 2 patients who received additional anti-CD20 infusions were excluded from subsequent analyses. Data are shown as medians and interquartile range (IQR). P -values were calculated by comparing the median values of each cell subpopulation between relapsing and nonrelapsing patients using a nonparametric, unpaired Mann–Whitney U test.

Journal: Kidney International Reports

Article Title: Early-Stage B-cells Predict Relapse After Rituximab Treatment in Patients With Membranous Nephropathy

doi: 10.1016/j.ekir.2026.106365

Figure Lengend Snippet: Reconstitution of B-cells over time. To characterize B-cell subsets, peripheral blood mononuclear cells were stained with fluorochrome-conjugated monoclonal antibodies (BD Biosciences) directed against the following antigens: CD45 (V500-C), CD3 (APC), CD19 (APC-H7), CD27 (BV421), IgD (PE), CD38 (BV711), CD4 (BV605), and CD8 (PE), as well as 7-AAD (Miltenyi Biotech). The stained cells were then analyzed using multicolor flow cytometry (BD FACS Lyric). The subsets of gated CD19 + cells were identified based on surface marker expression as follows: naïve (CD19+CD27-IgD+), nonswitched memory (CD19+CD27+IgD+), switched memory (CD19+CD27+IgD-), and double negative (CD19+CD27-IgD-); and within the CD19+CD38++ population, we distinguished transitional cells (CD19+CD38++CD27-IgD+), plasmablasts (CD19+CD38++CD27+IgD-), and double-negative CD38 + cells (CD19+CD38++CD27-IgD-). B-cell subsets were expressed as a percentage of the total lymphocyte count. (a) B-cell subpopulations were assessed in 39 patients at baseline and in 36 patients at 3 (M3), 6 (M6), 9 (M9), 12 (M12), and 18 (M18) months following the first rituximab infusion. The 3 patients who did not receive treatment were excluded from the follow-up. Complete depletion of B-cells was observed in all patients at M3 post-rituximab for all B-cell subpopulations. CD19 + cells reappeared 6 months after rituximab infusion. Naive cells re-emerged the most among B-cells, followed by CD38 + cells, transitional cells and finally memory cells. Data are shown as mean values (dots). (b–k) B-cell subpopulations at baseline and at subsequent time points were compared between relapsing patients ( n = 8) and nonrelapsing patients ( n = 19); the 2 patients who received additional anti-CD20 infusions were excluded from subsequent analyses. Data are shown as medians and interquartile range (IQR). P -values were calculated by comparing the median values of each cell subpopulation between relapsing and nonrelapsing patients using a nonparametric, unpaired Mann–Whitney U test.

Article Snippet: To characterize B-cell subsets, peripheral blood mononuclear cells were stained with fluorochrome-conjugated monoclonal antibodies (BD Biosciences) directed against the following antigens: CD45 (V500-C), CD3 (APC), CD19 (APC-H7), CD27 (BV421), IgD (PE), CD38 (BV711), CD4 (BV605), and CD8 (PE), as well as 7-AAD (Miltenyi Biotech).

Techniques: Staining, Bioprocessing, Flow Cytometry, Marker, Expressing, MANN-WHITNEY

Establishment and characterization of a fibrotic macrophage-muscle fibrosis model. a) Brightfield image of unstimulated RAW264.7 cells in the top chamber of a RAW-C2C12 coculture system, b) Brightfield image of C2C12 cells in the bottom chamber under basal coculture conditions, c) Fluorescence image of C2C12 cells in the bottom chamber exhibiting myotube morphology, d) Fluorescence image confirming the absence of fibrotic marker expression in C2C12 cells under basal conditions, e) Brightfield image of LPS-activated RAW264.7 cells in the top chamber, f) Brightfield image of C2C12 cells in the bottom chamber displaying a myofibroblast-like morphology post-LPS activation, g) Fluorescence image of phenotypic transition of C2C12 cells to myofibroblast-like cells, h) Fluorescence image demonstrating fibrotic protein expression in LPS-treated C2C12 cells (magenta arrow indicates CD38 cells). Immunostaining images: In panels c) and g), TGF-β, DAPI, and actin are colored red, blue, and green, respectively. In panels d) and h), COL1, α-SMA, CD38, and DAPI are colored red, blue, magenta, and green, respectively. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

Journal: Materials Today Bio

Article Title: Injectable antifibrotic drug-loaded hydrogels reduce fibrosis and restore myogenesis by enhancing mitochondrial metabolism and cell mechanics in an in vitro coculture model

doi: 10.1016/j.mtbio.2026.103033

Figure Lengend Snippet: Establishment and characterization of a fibrotic macrophage-muscle fibrosis model. a) Brightfield image of unstimulated RAW264.7 cells in the top chamber of a RAW-C2C12 coculture system, b) Brightfield image of C2C12 cells in the bottom chamber under basal coculture conditions, c) Fluorescence image of C2C12 cells in the bottom chamber exhibiting myotube morphology, d) Fluorescence image confirming the absence of fibrotic marker expression in C2C12 cells under basal conditions, e) Brightfield image of LPS-activated RAW264.7 cells in the top chamber, f) Brightfield image of C2C12 cells in the bottom chamber displaying a myofibroblast-like morphology post-LPS activation, g) Fluorescence image of phenotypic transition of C2C12 cells to myofibroblast-like cells, h) Fluorescence image demonstrating fibrotic protein expression in LPS-treated C2C12 cells (magenta arrow indicates CD38 cells). Immunostaining images: In panels c) and g), TGF-β, DAPI, and actin are colored red, blue, and green, respectively. In panels d) and h), COL1, α-SMA, CD38, and DAPI are colored red, blue, magenta, and green, respectively. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

Article Snippet: Mouse monoclonal antibodies against myosin heavy chain (MyHC), CD38, and transforming growth factor-β (TGF-β), as well as rabbit polyclonal α-smooth muscle actin (α-SMA) antibodies, were purchased from R&D Systems (USA).

Techniques: Fluorescence, Marker, Expressing, Activation Assay, Immunostaining

Immune pathology, B-cell characterization, and tertiary lymphoid organ-related features. a Diffuse relatively mild sarcolemmal MHC cl. 1 positivity and presence of many MHC cl. 1 positive lymphomonocytic cells in the endomysium, and in a B-cell cluster (arrow). MHC cl. 1 immunohistochemistry; original magnification ×200. b Mild and infrequent sarcolemmal MHC cl. 2 positivity and presence of many MHC cl. 2 positive lymphomonocytic cells in the endomysium, and in a B-cell cluster (arrow). MHC cl. 2 immunohistochemistry; original magnification ×200. c Sarcolemmal complement deposits (arrow) and presence of single necrotic myofibers (arrowhead) that show sarcoplasmic complement deposits. C5b-9 (MAC) immunohistochemistry; original magnification ×200. d Presence of numerous endomysial macrophages and occasional myophagocytoses. CD68 immunohistochemistry; original magnification ×200. e Scattered, individual endomysial T cells. CD8 immunohistochemistry; original magnification ×200. f Focally clustering B cells with a roundish appearance reminiscent of so-called tertiary lymphoid organs (TLOs). CD20 immunohistochemistry; original magnification ×200. g , h TLO-like immune cell clusters show compartmentalization with bcl2-positive B-cell nuclei at the margins and bcl6-positive nuclei in their (germinal) center. Bcl2 (G) and bcl6 (H) immunohistochemistry; original magnification ×600. i Numerous Ki67 + proliferating cells are focally clustering predominantly in germinal centers of TLOs. Ki67 immunohistochemistry; original magnification ×600. j A B-cell cluster contains some CD138-positive plasma cells. CD138 immunohistochemistry; original magnification ×200. k Similarly, those plasma cells and a few B cells are identified by nuclear MUM1 positivity in the light zone of a germinal center. MUM1 immunohistochemistry; original magnification ×200. l CD38-positive plasmablasts are partly proliferating and show co-immunoreactivity with Ki67. CD38 AF488 (green) and Ki67 Cy3 (red) immunofluorescence; original magnification ×200. a – l Scale bar represents 100 µm

Journal: Acta Neuropathologica

Article Title: Brachio-cervical inflammatory myopathy: multilevel clinical, histopathological and multi-omic analyses of a syndrome variably associated with systemic sclerosis

doi: 10.1007/s00401-026-03006-5

Figure Lengend Snippet: Immune pathology, B-cell characterization, and tertiary lymphoid organ-related features. a Diffuse relatively mild sarcolemmal MHC cl. 1 positivity and presence of many MHC cl. 1 positive lymphomonocytic cells in the endomysium, and in a B-cell cluster (arrow). MHC cl. 1 immunohistochemistry; original magnification ×200. b Mild and infrequent sarcolemmal MHC cl. 2 positivity and presence of many MHC cl. 2 positive lymphomonocytic cells in the endomysium, and in a B-cell cluster (arrow). MHC cl. 2 immunohistochemistry; original magnification ×200. c Sarcolemmal complement deposits (arrow) and presence of single necrotic myofibers (arrowhead) that show sarcoplasmic complement deposits. C5b-9 (MAC) immunohistochemistry; original magnification ×200. d Presence of numerous endomysial macrophages and occasional myophagocytoses. CD68 immunohistochemistry; original magnification ×200. e Scattered, individual endomysial T cells. CD8 immunohistochemistry; original magnification ×200. f Focally clustering B cells with a roundish appearance reminiscent of so-called tertiary lymphoid organs (TLOs). CD20 immunohistochemistry; original magnification ×200. g , h TLO-like immune cell clusters show compartmentalization with bcl2-positive B-cell nuclei at the margins and bcl6-positive nuclei in their (germinal) center. Bcl2 (G) and bcl6 (H) immunohistochemistry; original magnification ×600. i Numerous Ki67 + proliferating cells are focally clustering predominantly in germinal centers of TLOs. Ki67 immunohistochemistry; original magnification ×600. j A B-cell cluster contains some CD138-positive plasma cells. CD138 immunohistochemistry; original magnification ×200. k Similarly, those plasma cells and a few B cells are identified by nuclear MUM1 positivity in the light zone of a germinal center. MUM1 immunohistochemistry; original magnification ×200. l CD38-positive plasmablasts are partly proliferating and show co-immunoreactivity with Ki67. CD38 AF488 (green) and Ki67 Cy3 (red) immunofluorescence; original magnification ×200. a – l Scale bar represents 100 µm

Article Snippet: The antibodies used for immunohistochemistry included C5b-9 (Dako, aE11, 1:200), CD8 (Dako, C8/144B, 1:100), CD20 (Dako, Ks 20.8 1:200), Ki-67 (Dako, Mib-1, 1:100), MxA (Millipore, MABF938, 1:100), CD38 (Novocastra SPC32, 1:100), MUM1 (Dako, MUM1P, 1:50), CD45 (Dako, 2B11, 1:400), CD56 (Serotec/MCA591 ERIC-1, 1:400), CD68 (Dako, EBM11, 1:100), MHC class I (Dako, w6/32, 1:1000), MHC class II (Dako, CR3/43, 1:100), and SQSTM1/p62 (Abcam, polyclonal, 1:100).

Techniques: Cell Characterization, Immunohistochemistry, Clinical Proteomics, Immunofluorescence